Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

29 Apr 2010 09:02

RNS Number : 0230L
e-Therapeutics plc
29 April 2010
 



e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Issue of Equity and Director's award of Options

 

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 28 April 2010 , the Company issued and allotted 466,460 ordinary shares of 0.1p each in the Company (' Ordinary Shares') in order to satisfy the exercise of certain options.

 

Application has been made to admit the new Ordinary Shares to trading on AIM and dealings in the new Ordinary Shares are expected to commence on 5 May 2010. Following admission the number of Ordinary Shares in issue in the Company will be 65,886,752.

 

The above figure (65,886,752 Ordinary Shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules.

 

In addition to the above, two directors of the Company being Mr Oliver James and Mr Brad Hoy were both granted option over 25,000 ordinary shares in the Company at an exercise price of £0.385 and which have a vesting period of 3 years. Following this grant Mr James and Mr Hoy have the following interests in ordinary shares of the Company:

 

Name

Ordinary Shares owned

Options over Ordinary Shares

Number

Number

Exercise Price

Date at which exercisable

Oliver James

38,500

118,020

£0.67

Vested

25,000

£0.385

28 April 2013

Brad Hoy

80,000

£0.375

Vested

25,000

£0.385

28 April 2013

 

 

 

- Ends -

 

 

For more information:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

malcolm@etherapeutics.co.uk

+44 (0) 191 233 1317

Nominated Advisor & Broker:

Canaccord Adams Ltd

www.canaccordadams.com

Robert Finlay / Henry Fitzgerald-O'Connor

henry.fitzgerald-o'connor@canaccordadams.com

+44 (0) 20 7050 6500

Media enquiries:

Abchurch Communications

www.abchurch-group.com

Heather Salmond / Simone Elviss / Hannah Sharman

simone.elviss@abchurch-group.com

+44 (0) 20 7398 7700

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESEFSAUFSSESL
Date   Source Headline
10th Oct 200812:30 pmRNSPositive PhaseIIa trial of oral asthma drug
8th Oct 20087:00 amRNSInterim Results
15th Sep 20087:00 amRNSe-Therapeutics partners with KeyGen Biotechnology
4th Sep 20084:35 pmRNSDirectorate Change
21st Jul 20083:42 pmRNSFinal Results
6th May 20087:03 amRNSLaunch of Consultancy Service
4th Apr 20082:38 pmRNSDirector/PDMR Shareholding
5th Feb 200812:02 pmRNSHolding(s) in Company
22nd Jan 20087:01 amRNSETS2101 preclinical progress
10th Dec 200711:18 amRNSPreclinical Update
3rd Dec 20074:58 pmRNSDirector/PDMR Shareholding
28th Nov 20078:00 amRNSFirst day of dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.